
Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) – Equities researchers at Brookline Capital Markets upped their FY2026 earnings estimates for shares of Biomea Fusion in a research note issued on Thursday, November 12th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($0.55) per share for the year, up from their previous estimate of ($0.65). Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.57) per share. Brookline Capital Markets also issued estimates for Biomea Fusion’s FY2029 earnings at ($0.81) EPS and FY2030 earnings at ($0.85) EPS.
Several other research firms have also commented on BMEA. Wall Street Zen lowered shares of Biomea Fusion from a “hold” rating to a “sell” rating in a report on Saturday, October 24th. Citigroup reiterated a “market outperform” rating on shares of Biomea Fusion in a research note on Wednesday, September 30th. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Biomea Fusion in a report on Wednesday, October 14th. Citizens Jmp reissued a “market outperform” rating and issued a $7.00 price objective on shares of Biomea Fusion in a report on Wednesday, October 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, September 28th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Biomea Fusion has a consensus rating of “Moderate Buy” and an average target price of $7.60.
View Our Latest Research Report on BMEA
Biomea Fusion Price Performance
NASDAQ BMEA opened at $0.52 on Monday. The company has a market capitalization of $37.80 million, a PE ratio of -4.73 and a beta of -0.14. The company has a fifty day moving average of $1.10 and a 200 day moving average of $1.33. Biomea Fusion has a 1 year low of $0.52 and a 1 year high of $2.24.
Biomea Fusion (NASDAQ:BMEA – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12.
Hedge Funds Weigh In On Biomea Fusion
Several institutional investors have recently made changes to their positions in BMEA. Renaissance Technologies LLC lifted its stake in shares of Biomea Fusion by 174.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock valued at $2,009,000 after purchasing an additional 834,179 shares during the period. BlackRock Inc. acquired a new stake in Biomea Fusion during the second quarter valued at $1,052,000. GSA Capital Partners LLP acquired a new stake in Biomea Fusion during the second quarter valued at $318,000. ADAR1 Capital Management LLC acquired a new stake in Biomea Fusion during the second quarter valued at $64,000. Finally, Rathbones Group PLC acquired a new stake in Biomea Fusion during the first quarter valued at $57,000. 96.72% of the stock is owned by hedge funds and other institutional investors.
About Biomea Fusion
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer and metabolic diseases. Its research uses a platform designed to create covalent inhibitors, which bind to specific protein targets. The company’s lead drug candidate, icovamenib (BMF-219), is an oral menin inhibitor being studied for potential use in conditions including certain blood cancers and type 2 diabetes. Biomea Fusion is based in Redwood City, California, and was founded in 2017.
Featured Articles
- Five stocks we like better than Biomea Fusion
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
